72 related articles for article (PubMed ID: 38534332)
1. Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death.
Yamamoto Y; Sasaki N; Kumagai K; Takeuchi S; Toyooka T; Otani N; Wada K; Narita Y; Ichimura K; Namba H; Mori K; Tomiyama A
Neurol Med Chir (Tokyo); 2018 Jul; 58(7):296-302. PubMed ID: 29899179
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
[TBL] [Abstract][Full Text] [Related]
3. Exploring Regorafenib Responsiveness and Uncovering Molecular Mechanisms in Recurrent Glioblastoma Tumors through Longitudinal In Vitro Sampling.
Morelli M; Lessi F; Franceschi S; Ferri G; Giacomarra M; Menicagli M; Gambacciani C; Pieri F; Pasqualetti F; Montemurro N; Aretini P; Santonocito OS; Di Stefano AL; Mazzanti CM
Cells; 2024 Mar; 13(6):. PubMed ID: 38534332
[TBL] [Abstract][Full Text] [Related]
4. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
[TBL] [Abstract][Full Text] [Related]
5. Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy.
Urbantat RM; Jelgersma C; Brandenburg S; Nieminen-Kelhä M; Kremenetskaia I; Zollfrank J; Mueller S; Rubarth K; Koch A; Vajkoczy P; Acker G
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681839
[TBL] [Abstract][Full Text] [Related]
6. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lombardi G; De Salvo GL; Brandes AA; Eoli M; Rudà R; Faedi M; Lolli I; Pace A; Daniele B; Pasqualetti F; Rizzato S; Bellu L; Pambuku A; Farina M; Magni G; Indraccolo S; Gardiman MP; Soffietti R; Zagonel V
Lancet Oncol; 2019 Jan; 20(1):110-119. PubMed ID: 30522967
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma.
Chiang IT; Liu YC; Liu HS; Ali AAA; Chou SY; Hsu TI; Hsu FT
Neurotherapeutics; 2022 Mar; 19(2):616-634. PubMed ID: 35267171
[TBL] [Abstract][Full Text] [Related]
8. Molecular characteristics and therapeutic implications of Toll-like receptor signaling pathway in melanoma.
Guan H; Chen X; Liu J; Sun J; Guo H; Jiang Y; Zhang H; Zhang B; Lin J; Yuan Q
Sci Rep; 2023 Sep; 13(1):13788. PubMed ID: 37666853
[TBL] [Abstract][Full Text] [Related]
9. Correcting the drug development paradigm for glioblastoma requires serial tissue sampling.
Singh K; Hotchkiss KM; Parney IF; De Groot J; Sahebjam S; Sanai N; Platten M; Galanis E; Lim M; Wen PY; Minniti G; Colman H; Cloughesy TF; Mehta MP; Geurts M; Arrillaga-Romany I; Desjardins A; Tanner K; Short S; Arons D; Duke E; Wick W; Bagley SJ; Ashley DM; Kumthekar P; Verhaak R; Chalmers AJ; Patel AP; Watts C; Fecci PE; Batchelor TT; Weller M; Vogelbaum MA; Preusser M; Berger MS; Khasraw M
Nat Med; 2023 Oct; 29(10):2402-2405. PubMed ID: 37488293
[No Abstract] [Full Text] [Related]
10. Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges.
Duan C; Yu M; Xu J; Li BY; Zhao Y; Kankala RK
Biomed Pharmacother; 2023 Jun; 162():114643. PubMed ID: 37031496
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Glioblastoma Cells Response to Regorafenib.
Mongiardi MP; Buccarelli M; Formato A; Orecchini E; Salbini M; Ricci V; Orsini T; Putti S; Chiesa S; Ricci-Vitiani L; D'Alessandris QG; Pallini R; Levi A; Falchetti ML
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551679
[TBL] [Abstract][Full Text] [Related]
12. Metabolic-imaging of human glioblastoma live tumors: A new precision-medicine approach to predict tumor treatment response early.
Morelli M; Lessi F; Barachini S; Liotti R; Montemurro N; Perrini P; Santonocito OS; Gambacciani C; Snuderl M; Pieri F; Aquila F; Farnesi A; Naccarato AG; Viacava P; Cardarelli F; Ferri G; Mulholland P; Ottaviani D; Paiar F; Liberti G; Pasqualetti F; Menicagli M; Aretini P; Signore G; Franceschi S; Mazzanti CM
Front Oncol; 2022; 12():969812. PubMed ID: 36132155
[TBL] [Abstract][Full Text] [Related]
13. Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma.
Daniel P; Meehan B; Sabri S; Jamali F; Sarkaria JN; Choi D; Garnier D; Kitange G; Glennon KI; Paccard A; Karamchandani J; Riazalhosseini Y; Rak J; Abdulkarim B
Neurooncol Adv; 2022; 4(1):vdac076. PubMed ID: 35795471
[TBL] [Abstract][Full Text] [Related]
14. Early-Stage Loss of GALNT6 Predicts Poor Clinical Outcome in Colorectal Cancer.
Ogawa M; Tanaka A; Namba K; Shia J; Wang JY; Roehrl MH
Front Oncol; 2022; 12():802548. PubMed ID: 35692787
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
